BR112012009432A8 - Anticorpo anti-hsv e composição farmacêutica que o compreende - Google Patents

Anticorpo anti-hsv e composição farmacêutica que o compreende

Info

Publication number
BR112012009432A8
BR112012009432A8 BR112012009432A BR112012009432A BR112012009432A8 BR 112012009432 A8 BR112012009432 A8 BR 112012009432A8 BR 112012009432 A BR112012009432 A BR 112012009432A BR 112012009432 A BR112012009432 A BR 112012009432A BR 112012009432 A8 BR112012009432 A8 BR 112012009432A8
Authority
BR
Brazil
Prior art keywords
antibody
pharmaceutical composition
hsv
composition including
hsv antibody
Prior art date
Application number
BR112012009432A
Other languages
English (en)
Other versions
BR112012009432B1 (pt
BR112012009432A2 (pt
Inventor
Roggendorf Michael
Eis-Hübinger Anna-Maria
Krauss Jürgen
Eduard Schneweis Karl
Arndt Michaela
Krawczyk Adalbert
Exner Evelyn
P Däumer Martin
Original Assignee
Univ Duisburg Essen
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Univ Bonn Rheinische Friedrich Wilhelms
Heidelberg Immunotherapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duisburg Essen, Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Univ Bonn Rheinische Friedrich Wilhelms, Heidelberg Immunotherapeutics Gmbh filed Critical Univ Duisburg Essen
Publication of BR112012009432A2 publication Critical patent/BR112012009432A2/pt
Publication of BR112012009432A8 publication Critical patent/BR112012009432A8/pt
Publication of BR112012009432B1 publication Critical patent/BR112012009432B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ANTICORPO ANTI-HSV. A invenção refere-se a um anticorpo anti-HSV, conforme definido nas reivindicações, uma composição farmacêutica contendo uma quantidade eficaz do referido anticorpo, um vetor de expressão incluindo uma sequência de nucleotídeos que codifica o referido anticorpo, uma célula hospedeira compreendendo a referida sequência de nucleotídeos, uma célula de hibridoma capaz de produzir o referido anticorpo e ao uso do referido anticorpo como fármaco, em especial ao uso para a fabricação de um fármaco destinado ao tratamento profilático ou terapêutico de doenças associadas ao HSV em um indivíduo, conforme definido nas reivindicações.
BR112012009432A 2009-10-01 2010-10-01 anticorpo anti-hsv e composição farmacêutica que o compreende BR112012009432B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09012454A EP2308895A1 (en) 2009-10-01 2009-10-01 Anti-HSV antibody
PCT/EP2010/006020 WO2011038933A2 (en) 2009-10-01 2010-10-01 Anti-hsv antibody

Publications (3)

Publication Number Publication Date
BR112012009432A2 BR112012009432A2 (pt) 2016-11-29
BR112012009432A8 true BR112012009432A8 (pt) 2017-12-26
BR112012009432B1 BR112012009432B1 (pt) 2020-05-05

Family

ID=41716455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009432A BR112012009432B1 (pt) 2009-10-01 2010-10-01 anticorpo anti-hsv e composição farmacêutica que o compreende

Country Status (8)

Country Link
US (2) US8889137B2 (pt)
EP (3) EP2308895A1 (pt)
JP (3) JP5980681B2 (pt)
CN (2) CN104650222B (pt)
BR (1) BR112012009432B1 (pt)
CA (1) CA2776271C (pt)
ES (1) ES2715787T3 (pt)
WO (1) WO2011038933A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ726168A (en) * 2014-06-26 2022-05-27 Heidelberg Immunotherapeutics Gmbh Topical application for an anti-hsv antibody
EP3050897A1 (en) * 2015-01-28 2016-08-03 Polichem S.A. Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2
US10899824B2 (en) 2016-07-26 2021-01-26 Polichem S.A. Anti-HSV synergistic activity of antibodies and antiviral agents
WO2019044927A1 (ja) 2017-08-30 2019-03-07 Ｋｍバイオロジクス株式会社 改変型ＨＳＶ ｇＢタンパク質及びこれを含むＨＳＶワクチン
EP3677677A4 (en) * 2017-08-30 2021-09-22 KM Biologics Co., Ltd. MONOCLONAL ANTIBODY AGAINST HSV GB OR CORRESPONDING ANTIGEN BINDING FRAGMENT
CN110540998B (zh) * 2018-05-28 2024-01-05 深圳华大生命科学研究院 一种快速构建多价抗体表达载体的方法和试剂
CN113661176A (zh) * 2019-03-19 2021-11-16 阿尔伯特爱因斯坦医学院 用于预防和治疗单纯疱疹病毒感染的单克隆抗体
WO2021207348A1 (en) * 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP7260935B2 (ja) 2021-01-28 2023-04-19 国立研究開発法人農業・食品産業技術総合研究機構 対空標識、熱画像生成装置、熱画像生成方法、及びプログラム
US20230096087A1 (en) * 2021-09-24 2023-03-30 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie Prefusion-stabilized herpesvirus glycoprotein-b
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
CN117126253A (zh) * 2022-05-27 2023-11-28 江苏瑞科生物技术股份有限公司 Hsv免疫原性重组蛋白、其制备方法和应用、以及用其制备的疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5627227A (en) 1979-08-13 1981-03-17 Matsushita Electric Ind Co Ltd Display apparatus of dust collecting amount for electric cleaner
US4745182A (en) 1984-08-24 1988-05-17 University Patents, Inc. Herpes virus specific immunological materials and methods
DE3581400D1 (de) 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
US5646041A (en) 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH06135854A (ja) 1992-10-29 1994-05-17 Teijin Ltd 単純ヘルペスウイルス感染症治療剤
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody

Also Published As

Publication number Publication date
EP2483306B1 (en) 2019-01-02
US9657088B2 (en) 2017-05-23
EP2483306A2 (en) 2012-08-08
JP6663747B2 (ja) 2020-03-13
ES2715787T3 (es) 2019-06-06
CN104650222B (zh) 2017-08-18
CA2776271C (en) 2018-03-13
JP2018183148A (ja) 2018-11-22
WO2011038933A3 (en) 2011-06-30
US20150166638A1 (en) 2015-06-18
EP2308895A1 (en) 2011-04-13
BR112012009432B1 (pt) 2020-05-05
BR112012009432A2 (pt) 2016-11-29
WO2011038933A2 (en) 2011-04-07
JP2013506403A (ja) 2013-02-28
US20130058952A1 (en) 2013-03-07
CN102791733A (zh) 2012-11-21
JP2016147870A (ja) 2016-08-18
JP5980681B2 (ja) 2016-08-31
CA2776271A1 (en) 2011-04-07
CN102791733B (zh) 2015-03-11
US8889137B2 (en) 2014-11-18
CN104650222A (zh) 2015-05-27
JP6722233B2 (ja) 2020-07-15
EP3539983A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
BR112012009432A8 (pt) Anticorpo anti-hsv e composição farmacêutica que o compreende
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
PH12017501306A1 (en) Inhibitors of histone demethylases
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015013700A2 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
AU2011328009A8 (en) Compounds and methods for treating pain
AR069393A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
ECSP099332A (es) Moléculas de enlace de lingo y uso farmacéutico de las mismas
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112016004324A2 (pt) anticorpos
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
BR112012014066A2 (pt) preparações de combinações com exossomos e corticosteróide
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
EA201300592A1 (ru) Ингибиторы апоптоза и их применение

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFF

B25A Requested transfer of rights approved

Owner name: HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE)